Immatics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Immatics'in gelir ve kazançlarının sırasıyla 5.1% ve 22.8% yıllık düşüş göstermesi beklenirken, EPS'nin 17.2% azalması beklenmektedir.

Anahtar bilgiler

-22.8%

Kazanç büyüme oranı

-17.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.4%
Gelir büyüme oranı	-5.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	22 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18

Immatics reports Q3 results

Dec 02

Immatics (IMTX) Investor Presentation - Slideshow

Nov 13

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:IMTX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	50	-160	-183	N/A	5
12/31/2025	61	-137	-144	N/A	7
12/31/2024	116	-63	-134	N/A	6
9/30/2024	116	-56	-45	-20	N/A
6/30/2024	71	-74	-45	-17	N/A
3/31/2024	74	-80	-26	9	N/A
12/31/2023	54	-97	-13	18	N/A
9/30/2023	76	-84	-117	-92	N/A
6/30/2023	85	-79	-113	-94	N/A
3/31/2023	80	-68	-40	-31	N/A
12/31/2022	173	38	94	100	N/A
9/30/2022	151	34	97	102	N/A
6/30/2022	142	28	113	119	N/A
3/31/2022	130	15	38	44	N/A
12/31/2021	35	-93	-90	-85	N/A
9/30/2021	28	-95	-86	-81	N/A
6/30/2021	30	-231	-133	-127	N/A
3/31/2021	32	-226	-97	-91	N/A
12/31/2020	31	-211	-88	-81	N/A
9/30/2020	26	-208	-38	-31	N/A
6/30/2020	23	-49	75	81	N/A
3/31/2020	22	-34	55	60	N/A
12/31/2019	18	-32	69	71	N/A
12/31/2018	4	-31	20	21	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IMTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: IMTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: IMTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: IMTX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -5.1% ).

Yüksek Büyüme Geliri: IMTX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -5.1% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IMTX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Immatics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 7.9% to US$17.50

Consensus estimates of losses per share improve by 10%

Price target increased by 8.2% to US$19.83

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$18.25

Consensus EPS estimates increase by 76%

Recent updates

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $150.3125 million.

Immatics N.V. has filed a Follow-on Equity Offering.

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.9% to US$17.50

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 10%

New major risk - Revenue and earnings growth

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Price target increased by 8.2% to US$19.83

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 42%

Investor sentiment improves as stock rises 22%

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$18.25

Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021)

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 76%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame

Immatics launches $110M stock offering

Investor sentiment deteriorated over the past week

Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022

Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Price target decreased to US$20.00

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Price target decreased to US$22.80

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Consensus forecasts updated

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Consensus forecasts updated

Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.38 loss per share (vs €18.08 loss in 2Q 2020)

Supervisory Director Christof Hettich has left the company

Supervisory Director Christof Hettich has left the company

Consensus forecasts updated

First quarter 2021 earnings released: €0.34 loss per share (vs €7.14 loss in 1Q 2020)

Immatics Presents Preclinical Proof-Of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Full year 2020 earnings released: €4.77 loss per share (vs €0.95 loss in FY 2019)

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Immatics N.V., Annual General Meeting, Jun 17, 2021

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs